^
Association details:
| Biomarker: | ALK translocation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Regimen: | ABCP (Avastin (bevacizumab) + carboplatin + paclitaxel + Tecentriq (atezolizumab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
Published date:
10/20/2023
Excerpt:
A total of 228 patients with activating EGFR mutation (n=215) or ALK translocation (n=13) were enrolled from 16 sites in the Republic of Korea and randomized at 2:1 ratio to either ABCP (n=154) or PC arm (n=74….Objective response rates (69.5% vs 41.9%, P <0.001) and median PFS (8.48 vs. 5.62 months, hazard ratio [HR] 0.62 [0.45-0.86], P=0.004) were significantly better in the ABCP than PC arm.
DOI:
10.1200/JCO.23.01891
